Anthem Biosciences Limited (ANTHEM) Gross Profit 2022–TTM

Name: Anthem Biosciences Limited (ANTHEM) gross profit history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-01

Anthem Biosciences Limited annual gross profit for fiscal TTM was ₹12.7 billion, a decrease of 2.8% from ₹13.1 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

ANTHEM Annual Gross Profit

Gross Profit (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Gross Profit	₹12.7B	₹13.1B	₹11.0B	₹8.2B	₹7.2B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANTHEM Quarterly Gross Profit

Gross Profit (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Gross Profit	₹2.7B	₹4.0B	₹2.8B	₹3.3B	₹3.1B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Gross Profit at Comparable Companies

BIOCON Gross Profit — Biocon Limited
ABBV Gross Profit — AbbVie
6160 Gross Profit — BeOne Medicines AG
AMGN Gross Profit — Amgen
GILD Gross Profit — Gilead Sciences
VRTX Gross Profit — Vertex Pharmaceuticals

More ANTHEM metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow

All ANTHEM financial statements → Interactive ANTHEM charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.